CBAN Stock News 6.07 05/13/2014 11:39:42 Colony Bankcorp (CB

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Colony Bankcorp (CBAN) 6.07 $CBAN

Colony Bankcorp, Inc. Announces First Quarter Results
GlobeNewswire - Thu Apr 17, 7:00AM CDT
Colony Bankcorp, Inc. (Nasdaq:CBAN), today reported net income available to shareholders of $814,000, or $0.10 per diluted share for the first quarter of 2014 compared to $567,000, or $0.07 per diluted share for the comparable 2013 period. This increase of 43.56 percent in net income was primarily driven by an increase in net interest income and a reduction in provision for loan losses. "We are pleased to report first quarter operating results that reflect significant improvement in core earnings and strong regulatory capital. While loan demand is still less than robust, we continue to see signs of economic recovery that should result in loan activity picking up. While our substandard assets to tier one capital plus loan loss allowance ratio remained relatively flat this quarter, we have several transactions that should settle during second quarter to further reduce our problem assets," said Ed Loomis, President and Chief Executive Officer. "Efforts to reduce our problem assets and increase our outstanding loan balances will reinforce our balance sheet and further position our company for prolonged success."

Colony Bankcorp, Inc. Announces Fourth Quarter Results
GlobeNewswire - Fri Jan 24, 7:00AM CST
Colony Bankcorp, Inc. (Nasdaq:CBAN), today reported net income available to shareholders of $1,241,000, or $0.15 per diluted share for the fourth quarter of 2013 compared to $203,000, or $0.02 per diluted share for the comparable 2012 period, while net income available to shareholders for twelve months ended December 31, 2013 was $3,120,000, or $0.37 per diluted share compared to $1,206,000, or $0.14 per share for the comparable 2012 period. This increase of 158.71 percent in net income for the comparable twelve month period was primarily driven by an increase in net interest income and noninterest income (excluding securities gains) - along with a reduction in provision for loan losses. "In addition to significant core earnings improvement, Colony again had marked improvement in asset quality. Substandard assets to tier one capital plus loan loss allowance ratio improved to 39.22 percent at December 31, 2013 from 40.94 percent at September 30, 2013 and 55.60 percent at December 31, 2012. Though we were successful in having regulatory agencies lift the memorandum of understanding during 2013 and realized significant improvement in earnings and asset quality, we still are committed to reducing our problem assets to an acceptable level and returning to acceptable earnings," said Ed Loomis, President and Chief Executive Officer. "Momentum carrying over from 2013 initiatives has Colony positioned for a successful and productive year in 2014."

Colony Bankcorp, Inc. Announces Second Quarter Results
GlobeNewswire - Fri Jul 19, 7:00AM CDT
Colony Bankcorp, Inc. (Nasdaq:CBAN), today reported net income available to shareholders of $611,000, or $0.07 per diluted share for the second quarter of 2013 compared to $403,000, or $0.05 per diluted share for the comparable 2012 period, while net income available to shareholders for six months ended June 30, 2013 was $1,178,000, or $0.14 per diluted share compared to $592,000, or $0.07 per share for the comparable 2012 period. This increase of 98.99 percent in net income for the comparable six month period was primarily driven by an increase in net interest income and noninterest income - along with a reduction in provision for loan losses. "In addition to meaningful core earnings improvement, Colony again had marked improvement in asset quality. Substandard assets to tier one capital plus loan loss allowance ratio improved to 43.00 percent at June 30, 2013 from 45.85 percent at March 31, 2013. Though improvement was once again realized this quarter, we still have much work ahead to meet our goals of reducing our problem assets to an acceptable level and returning to acceptable earnings. Our board, management and staff remain committed to making incremental progress toward these goals during 2013," said Ed Loomis, President and Chief Executive Officer. "Though the economy continues to be less than robust and short term interest rates remain at historic low levels, we are cautiously optimistic that signs of economic recovery are surfacing. We had a modest increase in loans outstanding from the previous quarter end and have a healthy loan pipeline that should result in continued loan growth and core earnings improvement."

GUL, TIP, MGIC, CBAN, CWZ, ASIA Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Mar 15, 5:51AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Gulf Power Co (NYSE:GUL), iShares Barclays TIPS Bond Fund (NYSE:TIP), MAGIC SOFTWARE ENTERPRISES (NASDAQ:MGIC), Colony Bankcorp Inc (NASDAQ:CBAN), Lehman ABS Corp (NYSE:CWZ), Asiainfo Linkage Inc (NASDAQ:ASIA) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

CBAN, GNTX, FARO, CWST, TROW, VVC Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Jan 31, 4:57AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Colony Bankcorp Inc (NASDAQ:CBAN), Gentex Corp (NASDAQ:GNTX), FARO Technologies Inc (NASDAQ:FARO), Casella Waste Systems Inc (NASDAQ:CWST), T. Rowe Price Group Inc (NASDAQ:TROW), Vectren Corp (NYSE:VVC) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 316

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 0

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Stretch Zone Expands Horizons with Canadian Studio Launch

Updated Category News Views 214

Stretch Zone's Exciting New Chapter in Canada Stretch Zone, a trailblazer in the realm of assisted stretching, has embarked on a significant milestone by opening its first studio in Canada. This new location is not just a store but a powerful symbol of the brand's commitment to enhance flexibility and mobility in communities beyond the United States. The Vision Behind the...

Continue Reading
Eilean Therapeutics Unveils Groundbreaking JAK2 Inhibitor ZE74-0282

Updated Category News Views 585

New Frontiers in JAK2 Inhibition by Eilean Therapeutics Eilean Therapeutics LLC, a pioneering biotechnology company, is set to make waves in cancer treatment with its latest development, ZE74-0282, a wild-type-sparing JAK2-JH2/V617F inhibitor. The company has announced an exciting presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, focusing...

Continue Reading
PodcastOne Extends LadyGang Contract as It Approaches 1000 Episodes

Updated Category News Views 116

PodcastOne Renews its Agreement with LadyGang Podcast PodcastOne, a key player in the podcasting world, is thrilled to announce the renewal of its contract with the immensely popular LadyGang podcast, hosted by Keltie Knight, Becca Tobin, and Jac Vanek. Launched in 2015 on PodcastOne, this engaging podcast has resonated with millions of listeners and is gearing up to...

Continue Reading
BCA Research Warns Upcoming Rate Cuts May Be Insufficient

Updated Category News Views 73

BCA Research Warns Rate Cuts May Arrive Too Late BCA Research has expressed concerns about the upcoming rate cuts, suggesting they might not effectively address a potential recession. The firm points out that the effects of monetary policy often lag, meaning the economy is still grappling with the repercussions of previous tightening measures. Market Sentiments and...

Continue Reading
SOMOS Pilates Nashville: A Vibrant Rebranding Journey

Updated Category News Views 235

SOMOS Pilates Nashville: A Vibrant Rebranding Journey In an inspiring shift, Studio Pilates Nashville has announced its rebranding as SOMOS Pilates Nashville. This transition marks a significant evolution, aimed at celebrating the studio's growth and commitment to community-centered movement practices. Welcoming a New Identity The rebranding initiative reveals more than...

Continue Reading